Trevena preps low-key launch, responsible marketing for long-awaited opioid Olinvyk

Trevena notched its first drug approval last week with intravenous opioid Olinvyk. Now comes the tricky part—navigating the politics of marketing a new opioid product.

To do that, Trevena plans to take a narrowly focused approach, targeting healthcare professionals in acute care settings with a focus on complex patient types including elderly, obese and renally impaired people.